Rockefeller Capital Management
UNCY icon

Rockefeller Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Rockefeller Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.85K Buy
2,100
+500
+31% +$3.69K ﹤0.01% 4026
2026
Q1 		$10.5K Buy
1,600
+1,100
+220% +$7.21K ﹤0.01% 3971
2025
Q4 		$2.88K Hold
500
– – ﹤0.01% 4232
2025
Q3 		$2.18K Buy
+500
New +$2.18K ﹤0.01% 4074

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Rockefeller Capital Management's UNCY Position: Q2 2026 in Review

Rockefeller Capital Management increased its Unicycive Therapeutics (UNCY) stake by 31% in Q2 2026, buying an estimated $3.69K and bringing the position to 2,100 shares worth $9.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4026.

Rockefeller Capital Management first reported a position in UNCY in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.5K in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Rockefeller Capital Management held 2,100 shares of Unicycive Therapeutics worth $9.85K as of Q2 2026.
  • Rockefeller Capital Management bought 500 Unicycive Therapeutics shares in Q2 2026, an estimated $3.69K.
  • Unicycive Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4026 holding.
  • Rockefeller Capital Management first reported a position in Unicycive Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Unicycive Therapeutics position peaked at $10.5K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.